🧬 BioMed Pulse · 2026-11-09 02:01 UTC
BIOMED PULSE
Monday, November 9, 2026 | Daily Briefing on Longevity, Viruses & New Cures
⚡ TL;DR
The Bundibugyo virus (Ebola-type) outbreak in DRC has now spread to Kenya and Nigeria, making it the largest Ebola outbreak ever recorded and the dominant global health emergency of this moment. [1]
Mood: Elevated alarm on multiple outbreak fronts; longevity science continues its steady advance in parallel.
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO VIRUS (EBOLA) - DRC, KENYA, NIGERIA
- As of October 23, 2026, the DRC-origin Bundibugyo virus disease (BVD) outbreak has now reached Kenya and Nigeria via imported cases, representing the broadest geographic spread of any Ebola-type event on record. [1]
- WHO DON-622 confirms sustained, high-level transmission continues in DRC across multiple provinces including Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, Tshopo, and newly Sud Ubangi. [2] [1]
- As of July 15, 2026 (last firm confirmed WHO count), DRC alone had reported 2,124 confirmed cases and 828 deaths; case counts have accelerated rapidly since May. [3]
- A lab-confirmed imported BVD case in Kenya traveled from DRC through Uganda before hospitalization, illustrating the cross-border transmission pathway. [4]
- CDC activated airport Ebola screening at Washington-Dulles and Atlanta to catch travelers with DRC/Uganda exposure. [5] [6]
ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP
- The Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship has been the subject of five WHO Disease Outbreak News reports since notification on May 2, 2026, with severe acute respiratory illness cases confirmed among multiple nationalities. [7] [8]
- ANDV, unlike most hantavirus strains, is capable of person-to-person transmission, complicating containment in the cruise ship setting. [8]
- CDC issued multiple daily response transcripts in May and June 2026 and continues monitoring. [9] [10]
PNEUMONIA OF UNDETERMINED ETIOLOGY - RUSSIA
- On October 2, 2026, an employee of the Irkutsk Antiplague Research Institute (APRI) of Siberia and the Far East died from severe pneumonia of undetermined cause; WHO was alerted via media reports and is investigating the etiology.
- The institute handles dangerous pathogens, raising biosafety questions that WHO has not yet resolved publicly.
MERS-CoV - SAUDI ARABIA
- Between January 1 and October 5, 2026, Saudi Arabia reported 8 laboratory-confirmed MERS-CoV cases including 1 death, detected across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh (2 cases), and Tabuk.
- MERS-CoV remains endemic at low-level in the Arabian Peninsula; camel exposure remains the dominant zoonotic link.
NIPAH VIRUS - INDIA
- Kerala State, India confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district in June 2026; the adult male presented with neurological symptoms and was hospitalized on June 10.
- NiV carries a case fatality rate of 40-75% in historical outbreaks; Kerala health authorities have previous response experience from 2018 and 2023 events.
DRUG-RESISTANT BACTERIA
- A CDC report flagged a sharp, dramatic rise in dangerous drug-resistant bacteria in the U.S. as of September 2025, compounding the antimicrobial resistance threat.
- Extensively drug-resistant Salmonella linked to moringa powder capsules caused hospitalizations across multiple U.S. states as of February 2026, with 3 people hospitalized.
FOOD OUTBREAK SNAPSHOT
- CDC's ongoing Listeria outbreak linked to prepared meals has expanded to include additional products; 3 new illnesses and 1 additional death were reported in an update through late September 2025.
- A Salmonella outbreak linked to moringa leaf supplements had grown to 65 cases across 28 states as of January 29, 2026.
- Raw oysters drove a Salmonella outbreak reaching 64 people across 22 U.S. states as of December 2025.
🧬 LONGEVITY & AGING
GDF11 AND MUSCLE AGING
- A Europe PMC study published in Genes & Disease found that GDF11, a circulating growth differentiation factor, restores skeletal muscle satellite cell (stem cell) function via the MYC pathway to counteract sarcopenia, the age-related muscle wasting that is a major driver of frailty and mortality in older adults.
- Satellite cells are the repair units of muscle; their declining activation with age is a central mechanism in sarcopenia, and GDF11 appears to rejuvenate this pool.
AI-POWERED BIOLOGICAL AGE ESTIMATION FROM FACE PHOTOS
- A model development and validation study in Lancet Digital Health introduced FAHR-Face (Foundation Artificial Intelligence models for Health Recognition using face photographs), trained including work from Gladyshev VN's group, which estimates biological age and health risk from a standard facial photograph.
- The system could enable low-cost, scalable biological age screening without blood draws or imaging, a potentially transformative tool for longevity clinics and population studies.
AI VS CLINICIAN FOR CARDIAC MORTALITY PREDICTION
- A multicenter retrospective study in Lancet Digital Health found that AI-based left-ventricular segmentation of cardiac MRI outperformed clinician segmentation for all-cause mortality prediction, with researchers including teams from University College London.
- Improved cardiac phenotyping directly informs longevity risk stratification, since cardiovascular disease remains the leading cause of premature death globally.
STATIN DISCONTINUATION AND FRAILTY IN OLDER ADULTS
- A population-wide retrospective cohort study using Clinical Practice Research Datalink (England) examined statin discontinuation in patients aged 65 and older stratified by frailty status; published in Lancet Healthy Longevity.
- The accompanying editorial by Bardoczi and Rodondi noted that frailty status significantly modifies the risk-benefit calculation for statin continuation, a key deprescribing question in geriatric practice.
ANIMAL PROTEIN AND DEMENTIA RISK
- A global ecological analysis in Future Science OA found an association between higher national animal protein supply and slower cognitive aging, with data suggesting this factor may partially explain female-male dementia disparities across populations.
- The study is ecological and cannot establish individual-level causation, but adds to growing debate around dietary protein adequacy in older adults.
mTORC1 INHIBITION FOR DISC DEGENERATION
- Researchers published in Bioactive Materials demonstrated that cationized gelatin nanosphere-mediated RNA interference targeting mTORC1 protects against intervertebral disc degeneration in preclinical models; mTORC1 is also the primary target of rapamycin, the most studied longevity compound.
- Controlled local delivery of mTORC1 inhibition via nanospheres avoids the systemic immunosuppression that limits rapamycin's use in healthy aging contexts.
OSTEOARTHRITIS MICROENVIRONMENT REPROGRAMMING
- A DNA-adsorbing nanozyme hydrogel was shown in Bioactive Materials to reprogram the immuno-oxidative microenvironment of arthritic joints, supporting stem cell-based cartilage repair - targeting the chronic inflammation that drives OA progression in aging joints.
OLDER ADULTS IN HUMANITARIAN SETTINGS
- A series of papers in Lancet Healthy Longevity highlighted that older adults are systematically overlooked in humanitarian emergencies, with unmet needs in palliative care, nutrition, and sexual and reproductive health.
- The PARTICIPATE rights-based framework was proposed by van Boetzelaer et al. to formally include older people's health-care needs in humanitarian crisis responses.
💊 NEW CURES & APPROVALS
ORGOVYX SUPPLEMENT APPROVAL - PROSTATE CANCER
- Sumitomo Pharma Americas received a supplemental approval (SUPPL AP) for ORGOVYX (relugolix), an oral GnRH receptor antagonist, expanding its indications; originally approved for advanced prostate cancer.
- Relugolix is notable for its oral dosing and faster testosterone recovery versus injectable GnRH agonists, with relevance to aging men managing hormone-sensitive cancers.
ZYNLONTA SUPPLEMENT APPROVAL - B-CELL LYMPHOMA
- ADC Therapeutics SA received a supplemental approval for ZYNLONTA (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19 on B cells, under BLA761196.
- Loncastuximab tesirine delivers a DNA-damaging pyrrolobenzodiazepine dimer payload selectively to CD19-positive lymphoma cells.
HYDROXYUREA - ESJAY PHARMA (ORIGINAL APPROVAL)
- Esjay Pharma received an original ANDA approval for hydroxyurea, a ribonucleotide reductase inhibitor used in sickle cell disease and certain cancers; generic market expansion.
FLUTICASONE PROPIONATE - TEVA (ORIGINAL APPROVAL)
- Teva Pharmaceuticals USA received an original ANDA approval for fluticasone propionate, an inhaled corticosteroid used in asthma and COPD, commonly affecting older adults.
RELEUKO SUPPLEMENT - FILGRASTIM BIOSIMILAR
- Kashiv Biosciences received a supplemental approval for RELEUKO (filgrastim-ayow), a G-CSF biosimilar used to reduce infection risk from neutropenia in chemotherapy patients.
NOTE: openFDA supplement records in this batch carry no specific dated indication expansions; the above reflect approvals on file.
🧪 CLINICAL TRIALS
PEMBROLIZUMAB FOR NEUROLOGICAL LONG COVID
- A Phase I open-label safety trial (NCT07388550) is testing pembrolizumab, a PD-1 checkpoint inhibitor, for neurological post-acute sequelae of SARS-CoV-2 (neuro-PASC), listed on ClinicalTrials.gov as of November 6, 2026.
- The rationale is that persistent immune activation and T-cell exhaustion may drive neuro-PASC symptoms including headache, cognitive fog, and loss of smell; PD-1 blockade aims to reset this dysregulated immune state.
PSILOCYBIN PLUS COGNITIVE TRAINING FOR AGING BRAINS
- Trial NCT07721467 is investigating whether psilocybin combined with structured cognitive training can enhance neuroplasticity in older adults, targeting normal aging-related cognitive decline and Alzheimer's disease.
- The trial recruits adults with memory and attention changes; psilocybin is hypothesized to increase BDNF-mediated synaptic plasticity and improve the encoding of training gains.
ACUPRESSURE FOR EARLY ALZHEIMER'S DISEASE
- A randomized controlled trial (NCT07779863) is enrolling 188 older adults aged 60 to 85 years with early or mild Alzheimer's disease from care homes and elderly activity centers to test whether long-term acupressure slows disease progression.
RSV VACCINE IN ADULTS 60-PLUS IN CHINA
- Trial NCT06551181 is evaluating the immune response and efficacy of the GSK RSVPreF3 OA adjuvanted vaccine in Chinese adults aged 60 and older, comparing results to international cohorts from the ADJ-006 parent study.
- RSV is increasingly recognized as a major cause of serious respiratory illness and hospitalization in older adults globally.
MULTIDIMENSIONAL NUTRITIONAL PHENOTYPING FOR ELDERLY
- Trial NCT06163794 is using multifactorial phenotyping including gut microbiota, genotype, physical activity, and eating behaviors to personalize preventive nutritional support for elderly people, addressing the high inter-individual variability in dietary response seen with aging.
BRIEF BEHAVIORAL THERAPY FOR INSOMNIA IN OLDER ADULTS
- Trial NCT06073990 is testing nurse-led Brief Behavioral Therapy for Insomnia (BBTi) in middle-aged and older adults with chronic insomnia; poor sleep is a well-established accelerant of biological aging and dementia risk.
GERONTE - ICT-INTEGRATED GERIATRIC CARE PATHWAY
- A stepped-wedge randomized controlled trial (NCT05720910) across eight French hospitals is evaluating the GERONTE ICT-based integrated care pathway for improving 6-month quality of life in older cancer patients undergoing geriatric and oncological evaluation.
📢 PUBLIC HEALTH
DRUG-RESISTANT BACTERIA ON THE RISE
- CDC's September 2025 report documented a dramatic increase in drug-resistant bacteria across U.S. healthcare settings, calling for accelerated antibiotic stewardship efforts nationwide.
RABIES EXPOSURE INCREASING
- CDC issued a September 2026 statement on sharp increases in animal rabies activity and associated human exposures across the United States; residents in affected areas are urged to vaccinate pets and avoid wildlife contact.
CONGENITAL SYPHILIS HITS 12TH CONSECUTIVE RECORD YEAR
- New CDC data published September 2025 confirmed that U.S. newborn syphilis cases rose for the 12th year running in 2024, a persistent indicator of gaps in prenatal STI screening and treatment.
CANCER MORTALITY DECLINING, LED BY LUNG CANCER PROGRESS
- The 2026 Annual Report to the Nation found that progress against lung cancer, driven by low-dose CT screening uptake and improved therapies, is a primary driver of declining overall U.S. cancer mortality.
HEPATITIS B VACCINE POLICY SHIFT
- As of December 16, 2025, CDC formally adopted individual-based decision-making for hepatitis B immunization for infants born to mothers who test negative for hepatitis B virus, a shift away from universal birth-dose administration in that specific low-risk group.
TICK BITE ER VISITS ELEVATED
- CDC data from April 2026 showed weekly emergency-room visits for tick bites were running higher than seasonal norms; CDC advises use of EPA-registered repellents and clothing protection during outdoor activities.
WEST NILE EARLY AND ACTIVE
- As of July 1, 2026, CDC reported an early and record-paced West Nile virus season, urging Americans to take mosquito-bite precautions during summer and fall outdoor activities.
This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.
📎 Sources
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
- Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
- Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
- Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
- Transcript - Update on CDC's Hantavirus Response 5/13/2026 — CDC Newsroom
- Transcript - Update on CDC's Hantavirus Response 5/14/2026 — CDC Newsroom
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261109-02-v131 · 2026-11-09 02:01 UTC · pulse.uzylab.com